Back

Mavacamten for treatment of symptomatic mid-ventricular obstruction in hypertrophic cardiomyopathy: a case report

European Heart Journal - Case Reports

2 September 2025
Organised by: Logo
Read full article
ESC Journals VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Contributors

Samuel Hunziker
Samuel Hunziker

Author

Philip Haaf
Philip Haaf

Author

Annina S Vischer
Annina S Vischer

Author

University Hospital Basel Basel , Switzerland

Giacomo Tini Melato
Giacomo Tini Melato

Author

You may be interested in
thumbnail
Congress Presentation
The evolution of the obstructive HCM therapeutic landscape: emerging evidence about cardiac myosin inhibitors
31 August 2025
thumbnail
Congress Session
Cardiomyopathies cases
11 December 2025
thumbnail
Congress Presentation
Mitral regurgitation in obstructive hypertrophic cardiomyopathy: assessing the impact of mavacamten
13 December 2024
thumbnail
Congress Presentation
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources